Australia's most trusted
source of pharma news
Friday, 17 July 2026
Posted 17 July 2026 AM
Former Novartis ANZ Country President, Allison Rossiter, has joined Clarity Pharmaceuticals’ Board of Directors, revealing why the prostate cancer-focused company’s work is “personally significant”.
Rossiter’s new role as independent Non-Executive Director for the ASX-listed clinical stage radiopharmaceutical company comes exactly a month since she resigned from Novartis after three months in the top job, for personal reasons.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.